Published in Heart Vessels on April 20, 2011
NFAT transcription factor regulation by urocortin II in cardiac myocytes and heart failure. Am J Physiol Heart Circ Physiol (2014) 0.81
Effect of ouabain on myocardial ultrastructure and cytoskeleton during the development of ventricular hypertrophy. Heart Vessels (2012) 0.78
Regulation and roles of urocortins in the vascular system. Int J Endocrinol (2012) 0.75
Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest (2005) 4.31
GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov (2004) 3.93
The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J (2000) 3.64
Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A (2002) 3.27
Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res (2002) 2.32
Stabilization of beta-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth. Proc Natl Acad Sci U S A (2003) 2.01
The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci (2002) 1.84
Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest (2008) 1.76
Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br J Pharmacol (2008) 1.67
Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab (2002) 1.66
Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem (2008) 1.49
Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways. J Biol Chem (2006) 1.19
Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol (2002) 1.09
Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol (2000) 1.06
Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J Biol Chem (2001) 1.04
CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol (2004) 1.02
GSK3 inhibitors and disease. Mini Rev Med Chem (2009) 0.98
Plasma urocortin in human systolic heart failure. Clin Sci (Lond) (2004) 0.90
Glycogen synthase kinase-3beta -- actively inhibiting hypertrophy. Trends Cardiovasc Med (2007) 0.90
Urocortin modulates inflammatory response and neurotoxicity induced by microglial activation. J Immunol (2007) 0.90
Plasma urocortin 1 in human heart failure. Circ Heart Fail (2009) 0.86
Enhanced expression of the ubiquitin-proteasome system in the myocardium from patients with dilated cardiomyopathy referred for left ventriculoplasty: an immunohistochemical study with special reference to oxidative stress. Heart Vessels (2010) 0.85
Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway. Biochem Biophys Res Commun (2005) 0.83
Cardiotrophin-1 and urocortin cause protection by the same pathway and hypertrophy via distinct pathways in cardiac myocytes. Cytokine (2002) 0.82
Tumour necrosis factor-alpha activation of protein kinase B in WEHI-164 cells is accompanied by increased phosphorylation of Ser473, but not Thr308. Biochem J (2001) 0.82
Urocortin, a newly identified corticotropin-releasing factor-related mammalian peptide, stimulates atrial natriuretic peptide and brain natriuretic peptide secretions from neonatal rat cardiomyocytes. Biochem Biophys Res Commun (1998) 0.81
The use of H1-receptor antagonists and left ventricular remodeling in patients on chronic hemodialysis. Heart Vessels (2010) 0.81
Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3beta signaling pathway. Peptides (2010) 0.81
The nonpeptide AVE0991 attenuates myocardial hypertrophy as induced by angiotensin II through downregulation of transforming growth factor-beta1/Smad2 expression. Heart Vessels (2010) 0.81
Effects of urocortin II on neonatal rat cardiac myocytes and non-myocytes. Peptides (2005) 0.80
Urocortin modulates dopaminergic neuronal survival via inhibition of glycogen synthase kinase-3β and histone deacetylase. Neurobiol Aging (2009) 0.79
Circulating levels of stress associated peptide Urocortin in heart failure patients. Peptides (2009) 0.79
Urocortins: putative role in cardiovascular disease. Curr Med Chem Cardiovasc Hematol Agents (2004) 0.79
Urocortin: advancing the neurohumoral hypothesis of heart failure. Circulation (2005) 0.77
PI 3-kinase-Akt-p70 S6 kinase in hypertrophic responses to leukemia inhibitory factor in cardiac myocytes. Kobe J Med Sci (2003) 0.77
Protective effect of urocortin on 1-methyl-4-phenylpyridinium-induced dopaminergic neuronal death. Mol Cells (2010) 0.75
A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J (2003) 6.88
Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets. JAMA (2013) 4.69
Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut (2012) 3.09
Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol (2002) 2.73
What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J (2007) 2.52
Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol (2006) 2.47
Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. EMBO J (2003) 2.11
AMPK: Lessons from transgenic and knockout animals. Front Biosci (Landmark Ed) (2009) 2.09
Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. Am J Physiol Endocrinol Metab (2005) 2.04
EAE/ASE recommendations for the use of echocardiography in new transcatheter interventions for valvular heart disease. Eur Heart J (2011) 2.04
Role of the insulin-like growth factor I decline in the induction of atrogin-1/MAFbx during fasting and diabetes. Endocrinology (2004) 1.82
The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase. J Biol Chem (2002) 1.78
Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology. Eur Heart J (2004) 1.77
Direct comparison of whole-heart navigator-gated magnetic resonance coronary angiography and 40- and 64-slice multidetector row computed tomography to detect the coronary artery stenosis in patients scheduled for conventional coronary angiography. Circ Cardiovasc Imaging (2008) 1.77
Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation (2003) 1.71
Insulin signalling in the heart. Cardiovasc Res (2008) 1.55
Relationship between transmural extent of necrosis and quantitative recovery of regional strains after revascularization. JACC Cardiovasc Imaging (2010) 1.54
Cardiac and neurological assessment of normothermia/warm blood cardioplegia vs hypothermia/cold crystalloid cardioplegia in pediatric cardiac surgery: insight from a prospective randomized trial. Eur J Cardiothorac Surg (2011) 1.47
Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res (2003) 1.47
Long-term follow-up of DDD and VDD pacing: a prospective non-randomized single-centre comparison of patients with symptomatic atrioventricular block. Europace (2011) 1.45
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. Biochem J (2004) 1.45
Reconstructive surgery in active mitral valve endocarditis: feasibility, safety and durability. Eur J Cardiothorac Surg (2007) 1.44
Aortic valve area, stroke volume, left ventricular hypertrophy, remodeling, and fibrosis in aortic stenosis assessed by cardiac magnetic resonance imaging: comparison between high and low gradient and normal and low flow aortic stenosis. Circ Cardiovasc Imaging (2013) 1.42
Long-term mortality associated with left ventricular dysfunction in mitral regurgitation due to flail leaflets: a multicenter analysis. Circ Cardiovasc Imaging (2013) 1.41
Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes. Eur J Biochem (2002) 1.38
Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. Am J Physiol Endocrinol Metab (2009) 1.38
Effects of preoperative aortic insufficiency on outcome after aortic valve-sparing surgery. Circulation (2009) 1.33
Long-term survival in asymptomatic patients with severe degenerative mitral regurgitation: a propensity score-based comparison between an early surgical strategy and a conservative treatment approach. J Thorac Cardiovasc Surg (2009) 1.28
Evaluation of anatomic valve opening and leaflet morphology in aortic valve bioprosthesis by using multidetector CT: comparison with transthoracic echocardiography. Radiology (2009) 1.27
AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc Res (2011) 1.24
Repair of regurgitant bicuspid aortic valves: a systematic approach. J Thorac Cardiovasc Surg (2010) 1.23
EAE/ASE recommendations for the use of echocardiography in new transcatheter interventions for valvular heart disease. J Am Soc Echocardiogr (2011) 1.21
Valve sparing-root replacement with the reimplantation technique to increase the durability of bicuspid aortic valve repair. J Thorac Cardiovasc Surg (2011) 1.20
H11 kinase prevents myocardial infarction by preemptive preconditioning of the heart. Circ Res (2005) 1.19
Comparison of three instruments assessing the quality of economic evaluations: a practical exercise on economic evaluations of the surgical treatment of obesity. Int J Technol Assess Health Care (2008) 1.19
AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. Am J Physiol Heart Circ Physiol (2006) 1.14
Head-to-head comparison of three-dimensional navigator-gated magnetic resonance imaging and 16-slice computed tomography to detect coronary artery stenosis in patients. J Am Coll Cardiol (2005) 1.14
Role of the ductal transcription factors HNF6 and Sox9 in pancreatic acinar-to-ductal metaplasia. Gut (2012) 1.14
Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem (2005) 1.12
Signalling pathways and combinatory effects of insulin and amino acids in isolated rat hepatocytes. Eur J Biochem (2002) 1.12
Myocardial ischemia and increased heart work modulate the phosphorylation state of eukaryotic elongation factor-2. J Biol Chem (2003) 1.10
Assessment and repair of aortic valve cusp prolapse: implications for valve-sparing procedures. J Thorac Cardiovasc Surg (2011) 1.09
High-resolution X-ray structures of human apoferritin H-chain mutants correlated with their activity and metal-binding sites. J Mol Biol (2006) 1.08
Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol (2011) 1.05
Assessment of subendocardial vs. subepicardial left ventricular rotation and twist using two-dimensional speckle tracking echocardiography: comparison with tagged cardiac magnetic resonance. Eur Heart J (2008) 1.05
Restoring specific lactobacilli levels decreases inflammation and muscle atrophy markers in an acute leukemia mouse model. PLoS One (2012) 1.04
Role of the alpha2-isoform of AMP-activated protein kinase in the metabolic response of the heart to no-flow ischemia. Am J Physiol Heart Circ Physiol (2006) 1.04
Magnetic resonance imaging evaluation of cerebral embolization during percutaneous aortic valve implantation: comparison of transfemoral and trans-apical approaches using Edwards Sapiens valve. Eur J Cardiothorac Surg (2011) 1.03
Identification of in vivo phosphorylation sites on human deoxycytidine kinase. Role of Ser-74 in the control of enzyme activity. J Biol Chem (2005) 1.03
Insulin and ischemia stimulate glycolysis by acting on the same targets through different and opposing signaling pathways. J Mol Cell Cardiol (2002) 1.02
EAE/ASE recommendations for the use of echocardiography in new transcatheter interventions for valvular heart disease. Eur J Echocardiogr (2011) 1.01
NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc Res (2011) 1.01
Crucial role for LKB1 to AMPKalpha2 axis in the regulation of CD36-mediated long-chain fatty acid uptake into cardiomyocytes. Biochim Biophys Acta (2008) 1.01
Cusp prolapse repair in trileaflet aortic valves: free margin plication and free margin resuspension techniques. Ann Thorac Surg (2009) 0.99
Dual cardiac contractile effects of the alpha2-AMPK deletion in low-flow ischemia and reperfusion. Am J Physiol Heart Circ Physiol (2007) 0.99
Intermediate follow-up results from the multicenter engager European pivotal trial. Ann Thorac Surg (2013) 0.98
Role of Activin A and myostatin in human cancer cachexia. J Clin Endocrinol Metab (2015) 0.98
Activation of the cardiac mTOR/p70(S6K) pathway by leucine requires PDK1 and correlates with PRAS40 phosphorylation. Am J Physiol Endocrinol Metab (2010) 0.98
Myocardial delivery of colloid nanoparticles using ultrasound-targeted microbubble destruction. Eur Heart J (2005) 0.96
Respiratory-related heart rate variability in progressive experimental heart failure. Am J Physiol Heart Circ Physiol (2005) 0.96
Incidence, determinants, and prognostic impact of operative refusal or denial in octogenarians with severe aortic stenosis. Ann Thorac Surg (2011) 0.95
Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail (2004) 0.95
Increased plasma myostatin in heart failure. Eur J Heart Fail (2011) 0.95
Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity. Biochem Biophys Res Commun (2009) 0.95
IGF-I does not prevent myotube atrophy caused by proinflammatory cytokines despite activation of Akt/Foxo and GSK-3beta pathways and inhibition of atrogin-1 mRNA. Am J Physiol Endocrinol Metab (2006) 0.95
Risk of valve-related events after aortic valve repair. Ann Thorac Surg (2012) 0.94
Imaging in the management of ischemic cardiomyopathy: special focus on magnetic resonance. J Am Coll Cardiol (2012) 0.94
Impairment of liver GH receptor signaling by fasting. Endocrinology (2002) 0.93
Contribution of exercise-induced mitral regurgitation to exercise stroke volume and exercise capacity in patients with left ventricular systolic dysfunction. Circulation (2002) 0.93
Role of IGF-I and IGFBPs in the changes of mass and phenotype induced in rat soleus muscle by clenbuterol. Am J Physiol Endocrinol Metab (2002) 0.93
Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab (2002) 0.93
ER stress induces anabolic resistance in muscle cells through PKB-induced blockade of mTORC1. PLoS One (2011) 0.93
Repair of bicuspid aortic valves in patients with aortic regurgitation. Circulation (2006) 0.92
Early activation of cardiac and renal endothelin systems in experimental heart failure. Am J Physiol Heart Circ Physiol (2003) 0.91
Enhanced activation of cellular AMPK by dual-small molecule treatment: AICAR and A769662. Am J Physiol Endocrinol Metab (2014) 0.91
Lactate stimulates angiogenesis and accelerates the healing of superficial and ischemic wounds in mice. Angiogenesis (2012) 0.91
C-terminal FGF23 is a strong predictor of survival in systolic heart failure. Peptides (2012) 0.90
Myocardial injury induced by ultrasound-targeted microbubble destruction: evidence for the contribution of myocardial ischemia. Ultrasound Med Biol (2008) 0.90
The relationship between p38 mitogen-activated protein kinase and AMP-activated protein kinase during myocardial ischemia. Cardiovasc Res (2007) 0.89